Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

“According to the latest figures released by the NHS, dementia diagnosis is at a record high in England. ... Pharmacist cautions against self-medicating with ozempic for dementia risk reduction.

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

It comes as separate research from scientists in Ireland today suggested that GLP-1RAs were also 'associated with a statistically significant reduction in dementia'.

A few years later, in a study published in the journal Alzheimer's & Dementia, Dr Knudsen and colleagues sampled nearly 16,000 people and gave one group a drug in the same class as Ozempic while ...

New study suggests that Novo Nordisk’s Ozempic may lower dementia risk and nicotine use. Meanwhile, UnitedHealth Group’s cyberattack woes aren’t over yet.

has found that its “miracle” weight loss drug used for diabetes, Ozempic, is linked to a significant reduction in the risk of dementia and other cognitive issues. What Happened: A study ...

Ozempic was also linked to a greater reduction in Alzheimer’s risk compared with metformin and several other older diabetes drugs. Brain health benefits of Ozempic didn’t change based on ...

A study finds a drug known for weight loss may also help to reduce dementia. The study looked at semaglutide, the scientific name for Novo Nordisk's (NVO) (DK:NOVO.B) Ozempic, with the intent of ...

The first study to assess how weight-loss drugs affect the whole of human health has discovered an "eye-opening" impact on the body, researchers say. The analysis, involving about two million ...